Guadalupe Zafra-Hernández, Karla E. Pérez-Reséndiz, Rosalba Moreno-Alcantar, Ricardo Sandoval-Salas
{"title":"Lactate-albumin ratio as a predictor of mortality in patients with acute on chronic liver failure in a third-level care hospital in Mexico","authors":"Guadalupe Zafra-Hernández, Karla E. Pérez-Reséndiz, Rosalba Moreno-Alcantar, Ricardo Sandoval-Salas","doi":"10.1016/j.aohep.2024.101442","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>Acute-on-chronic liver failure (ACLF) is an abrupt worsening of clinical conditions in patients with chronic liver disease. It has a higher mortality rate with respect to patients who do not develop this entity (33.9% vs. 4.7%). The lactate/albumin ratio is a statistically significant predictor (p<0.001) of mortality during hospitalization in these patients. This study aimed to determine whether the lactate-albumin ratio predicts mortality in patients with ACLF in Mexican population, identify the sociodemographic characteristics of this group of patients and to determine the related mortality at 7, 28, 90 and 180 days.</p></div><div><h3>Materials and Patients</h3><p>An observational, retrospective, single-center study was conducted where patients with diagnosis of ACLF according to the EASL-CLIF criteria who were hospitalized during the period from 2017 to 2022 in the Gastroenterology department at National Medical Centre \"Siglo XXI\" were included. Patients diagnosed with terminal chronic extrahepatic diseases, hepatocellular carcinoma and extrahepatic neoplasms were excluded.</p></div><div><h3>Results</h3><p>A total of 186 patients were enrolled, 51% were women, with an age range of 56-65 years, 29% were secondary to fatty liver disease associated with metabolic dysfunction, obtaining that the most frequent precipitant was the infectious origin in 111 patients (60%), with abdominal origin being the most prevalent (36%). Renal failure was present in 71%, followed by coagulopathy (50%) and neurological failure (49%). On admission, grade I ACLF was present in 37 patients (20%), grade II in 72 (39%), grade III in 77 (49%). At 7, 28, 28, 90 and 180 days 73 patients (39.5%), 146 patients (78.9%), 159 (85.9%) and 172 patients (93%) died respectively, with a lactate albumin ratio for each of these, with a cut-off point 1.24 (AUC 70.70%), 0.87(AUC 71.20%), 0.84 (AUC 73.5%) and 1.04(AUC 64.90%) respectively with statistically significant values p <0.05.</p></div><div><h3>Conclusions</h3><p>Lactate levels and its clearance have been shown to predict outcome of critically ill patients with liver cirrhosis, improving the prediction of mortality. The lactate albumin ratio is useful for predicting mortality in this group of patients at 7, 28, 90 and 180 days with adequate sensitivity and specificity. The values obtained were statistically significant as shown in the complementary tables.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268124002369/pdfft?md5=44719179eb705c2c3bb034b707cdc1af&pid=1-s2.0-S1665268124002369-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268124002369","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and Objectives
Acute-on-chronic liver failure (ACLF) is an abrupt worsening of clinical conditions in patients with chronic liver disease. It has a higher mortality rate with respect to patients who do not develop this entity (33.9% vs. 4.7%). The lactate/albumin ratio is a statistically significant predictor (p<0.001) of mortality during hospitalization in these patients. This study aimed to determine whether the lactate-albumin ratio predicts mortality in patients with ACLF in Mexican population, identify the sociodemographic characteristics of this group of patients and to determine the related mortality at 7, 28, 90 and 180 days.
Materials and Patients
An observational, retrospective, single-center study was conducted where patients with diagnosis of ACLF according to the EASL-CLIF criteria who were hospitalized during the period from 2017 to 2022 in the Gastroenterology department at National Medical Centre "Siglo XXI" were included. Patients diagnosed with terminal chronic extrahepatic diseases, hepatocellular carcinoma and extrahepatic neoplasms were excluded.
Results
A total of 186 patients were enrolled, 51% were women, with an age range of 56-65 years, 29% were secondary to fatty liver disease associated with metabolic dysfunction, obtaining that the most frequent precipitant was the infectious origin in 111 patients (60%), with abdominal origin being the most prevalent (36%). Renal failure was present in 71%, followed by coagulopathy (50%) and neurological failure (49%). On admission, grade I ACLF was present in 37 patients (20%), grade II in 72 (39%), grade III in 77 (49%). At 7, 28, 28, 90 and 180 days 73 patients (39.5%), 146 patients (78.9%), 159 (85.9%) and 172 patients (93%) died respectively, with a lactate albumin ratio for each of these, with a cut-off point 1.24 (AUC 70.70%), 0.87(AUC 71.20%), 0.84 (AUC 73.5%) and 1.04(AUC 64.90%) respectively with statistically significant values p <0.05.
Conclusions
Lactate levels and its clearance have been shown to predict outcome of critically ill patients with liver cirrhosis, improving the prediction of mortality. The lactate albumin ratio is useful for predicting mortality in this group of patients at 7, 28, 90 and 180 days with adequate sensitivity and specificity. The values obtained were statistically significant as shown in the complementary tables.
期刊介绍:
Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.